文献速递糖尿病

DETO2X-AMI试验预设亚组:糖尿病与非糖尿病心梗患者的氧疗效果

Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial.
PubMed 文献 · Diabetes Care · 2019-08-31

DETO2X-AMI试验将6629例疑似心梗且血氧正常的患者随机分配至6 L/min氧疗6-12小时或环境空气组,本预设分析纳入5010例确诊心梗患者(934例已知糖尿病)。糖尿病患者的复合终点事件率显著更高(HR 1.60,95%CI 1.32-1.93,P<0.01),但氧疗对1年全因死亡、心血管死亡或心梗/心衰再住院的影响在糖尿病与非糖尿病患者中均无显著差异。

要点

  • 糖尿病患者心梗后1年复合终点事件率显著高于非糖尿病患者(HR 1.60,95%CI 1.32-1.93)。
  • 氧疗对糖尿病患者1年复合终点无显著影响(16.2% vs 16.6%,HR 0.93,95%CI 0.67-1.27,P=0.81)。
  • 无论是否合并糖尿病,氧疗均未显著改变1年全因死亡、心血管死亡或再住院风险。

核心结论

  • 在血氧正常的心梗患者中,无论是否合并糖尿病,氧疗均未显著影响1年全因死亡、心血管死亡或心梗/心衰再住院。
  • 糖尿病患者心梗后事件率显著高于非糖尿病患者,但氧疗效果不受糖尿病状态影响。

研究设计与样本

  • DETO2X-AMI试验的预设亚组分析,将6629例血氧正常的疑似心梗患者随机分配至6 L/min氧疗6-12小时或环境空气组。
  • 本分析纳入5010例确诊心梗患者,其中934例有已知糖尿病。

主要发现

  • 糖尿病患者主要复合终点事件率显著高于非糖尿病患者(HR 1.60,95%CI 1.32-1.93,P<0.01)。
  • 糖尿病组中氧疗组主要复合终点发生率为16.2%(72/445),环境空气组为16.6%(81/489),HR 0.93(95%CI 0.67-1.27),P=0.81。
  • 复合终点各单独组分及1年内心血管死亡率在治疗组间均无统计学显著差异。
  • 非糖尿病患者中相应终点在治疗组间同样相似。

临床怎么用

  • 对于血氧正常的心梗患者,无论是否合并糖尿病,不应常规给予 supplemental oxygen 以改善1年心血管结局。

局限性

  • 本分析为预设亚组分析,糖尿病患者样本量有限(934例),可能不足以检测小幅效应。
  • 研究仅纳入血氧正常患者,结论不适用于低氧血症心梗患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the effects of oxygen therapy in myocardial infarction (MI) patients with and without diabetes. RESEARCH DESIGN AND METHODS: In the Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) trial, 6,629 normoxemic patients with suspected MI were randomized to oxygen at 6 L/min for 6-12 h or ambient air. In this prespecified analysis involving 5,010 patients with confirmed MI, 934 had known diabetes. Oxidative stress may be of particular importance in diabetes, and the primary objective was to study the effect of supplemental oxygen on the composite of all-cause death and rehospitalization with MI or heart failure (HF) at 1 year in patients with and without diabetes. RESULTS: As expected, event rates were significantly higher in patients with diabetes compared with patients without diabetes (main composite end point: hazard ratio [HR] 1.60 [95% CI 1.32-1.93], P < 0.01). In patients with diabetes, the main composite end point occurred in 16.2% (72 of 445) allocated to oxygen as compared with 16.6% (81 of 489) allocated to ambient air (HR 0.93 [95% CI 0.67-1.27], P = 0.81). There was no statistically significant difference for the individual components of the composite end point or the rate of cardiovascular death up to 1 year. Likewise, corresponding end points in patients without diabetes were similar between the treatment groups. CONCLUSIONS: Despite markedly higher event rates in patients with MI and diabetes, oxygen therapy did not significantly affect 1-year all-cause death, cardiovascular death, or rehospitalization with MI or HF, irrespective of underlying diabetes, in line with the results of the entire study.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Nyström T, James SK, Lindahl B, et al. Oxygen Therapy in Myocardial Infarction Patients With or Without Diabetes: A Predefined Subgroup Analysis From the DETO2X-AMI Trial. Diabetes Care. 2019. PMID: 31473600. doi:10.2337/dc19-0590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。